Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Stocks in this Quantisnow insightHealth Care
Historical context for PSTV
Across the 28 sessions after earlier PSTV headlines, the stock closed higher 11 times and lower 17 times, with a median move of 6.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PSTV | SPY |
|---|---|---|---|
| May 18, 2026 | Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout | +11.2% | -0.1% |
| May 7, 2026 | Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic | -0.8% | -0.3% |
| Apr 28, 2026 | Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer | -0.7% | -0.5% |
| Apr 23, 2026 | Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™and 1 other headline that session | -4.5% | -0.4% |
| Apr 21, 2026 | Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | -2.2% | -0.7% |
| Apr 15, 2026 | Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution | +4.1% | +0.8% |
Quantisnow market dataNASDAQ
PSTV
PLUS THERAPEUTICS Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
Get push alerts for PSTV
Full PSTV profile on Quantisnow Follow PSTV and get a push notification the moment its next story breaks.